BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1210 related articles for article (PubMed ID: 17453358)

  • 1. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
    Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
    Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
    Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
    Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification.
    Parsons MT; Buchanan DD; Thompson B; Young JP; Spurdle AB
    J Med Genet; 2012 Mar; 49(3):151-7. PubMed ID: 22368298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing.
    Domingo E; Laiho P; Ollikainen M; Pinto M; Wang L; French AJ; Westra J; Frebourg T; Espín E; Armengol M; Hamelin R; Yamamoto H; Hofstra RM; Seruca R; Lindblom A; Peltomäki P; Thibodeau SN; Aaltonen LA; Schwartz S
    J Med Genet; 2004 Sep; 41(9):664-8. PubMed ID: 15342696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
    Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
    Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and molecular detection of inherited colorectal cancers in northeast Italy: a first prospective study of incidence of Lynch syndrome and MUTYH-related colorectal cancer in Italy.
    Urso E; Agostini M; Pucciarelli S; Rugge M; Bertorelle R; Maretto I; Bedin C; D'Angelo E; Mescoli C; Zorzi M; Viel A; Bruttocao G; Ferraro B; Erroi F; Contin P; De Salvo GL; Nitti D
    Tumour Biol; 2012 Jun; 33(3):857-64. PubMed ID: 22278153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular testing for microsatellite instability and DNA mismatch repair defects in hereditary and sporadic colorectal cancers--ready for prime time?
    Søreide K
    Tumour Biol; 2007; 28(5):290-300. PubMed ID: 17962726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes.
    Domingo E; Niessen RC; Oliveira C; Alhopuro P; Moutinho C; Espín E; Armengol M; Sijmons RH; Kleibeuker JH; Seruca R; Aaltonen LA; Imai K; Yamamoto H; Schwartz S; Hofstra RM
    Oncogene; 2005 Jun; 24(24):3995-8. PubMed ID: 15782118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.
    Bessa X; Ballesté B; Andreu M; Castells A; Bellosillo B; Balaguer F; Castellví-Bel S; Paya A; Jover R; Alenda C; Titó L; Martinez-Villacampa M; Vilella A; Xicola RM; Pons E; Llor X;
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):206-14. PubMed ID: 18096441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic testing for hereditary nonpolyposis colorectal cancer.
    Hoedema R; Monroe T; Bos C; Palmer S; Kim D; Marvin M; Luchtefeld M
    Am Surg; 2003 May; 69(5):387-91; discussion 391-2. PubMed ID: 12769209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
    Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
    Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
    Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
    Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer.
    McGivern A; Wynter CV; Whitehall VL; Kambara T; Spring KJ; Walsh MD; Barker MA; Arnold S; Simms LA; Leggett BA; Young J; Jass JR
    Fam Cancer; 2004; 3(2):101-7. PubMed ID: 15340260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causes of microsatellite instability in colorectal tumors: implications for hereditary non-polyposis colorectal cancer screening.
    Potocnik U; Glavac D; Golouh R; Ravnik-Glavac M
    Cancer Genet Cytogenet; 2001 Apr; 126(2):85-96. PubMed ID: 11376800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.
    Niessen RC; Berends MJ; Wu Y; Sijmons RH; Hollema H; Ligtenberg MJ; de Walle HE; de Vries EG; Karrenbeld A; Buys CH; van der Zee AG; Hofstra RM; Kleibeuker JH
    Gut; 2006 Dec; 55(12):1781-8. PubMed ID: 16636019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary nonpolyposis colorectal cancer in endometrial cancer patients.
    Yoon SN; Ku JL; Shin YK; Kim KH; Choi JS; Jang EJ; Park HC; Kim DW; Kim MA; Kim WH; Lee TS; Kim JW; Park NH; Song YS; Kang SB; Lee HP; Jeong SY; Park JG
    Int J Cancer; 2008 Mar; 122(5):1077-81. PubMed ID: 17973265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.